Skip to main content
Curocell Inc. logo

Curocell Inc. — Investor Relations & Filings

Ticker · 372320 ISIN · KR7372320002 KO Manufacturing
Open in API
Filings indexed 110 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country KR South Korea
Listing KO 372320

About Curocell Inc.

https://curocellbtx.com/

Curocell Inc. is a clinical-stage biotechnology company specializing in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on engineering a patient's own immune cells to recognize and eliminate cancer, primarily targeting blood cancers. Curocell's proprietary OVIS™ technology is an immune checkpoint receptor platform designed to enhance the efficacy of CAR-T treatments by overcoming the immunosuppressive tumor microenvironment. The company has advanced its lead candidate, anbalcabtagene autoleucel (Limkato), through Phase 2 clinical trials and operates a state-of-the-art GMP facility for the production of its advanced cell therapies.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Regulatory Filings
2026-05-07 Korean
투자판단관련주요경영사항 (림카토주(안발셀) 식품의약품안전처 품목허가 승인)
Regulatory Filings Classification · 1% confidence The document is a Korean stock exchange disclosure titled “투자판단 관련 주요경영사항” announcing MFDS approval of a pharmaceutical product. It is a regulatory announcement of a corporate event, not a financial report, earnings release, or other specific filing type. It falls under general regulatory filings (fallback category).
2026-04-29 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 1% confidence The document is a self-disclosed notice detailing the results of a securities issuance (4th series private convertible bonds) including issuance amount, board resolution date, payment date, and listing intention. This constitutes an update on the company’s financing activities / capital structure change rather than an earnings release, board change, or full report. Accordingly, it fits the Capital/Financing Update category.
2026-04-27 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 1% confidence The document details the results of a securities issuance (type of security, issuance method, share count, amounts, payment date), which is specifically an announcement of new share issuance via third-party allotment. This fits the definition of Share Issue/Capital Change (SHA) rather than a broad funding update or regulatory notice.
2026-04-27 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a Korean "주요사항보고서" (Material Event Report) filed with the Financial Supervisory Service and Korea Exchange, detailing the terms of a new issuance of 36.35 billion KRW in convertible bonds (including conversion price adjustments, maturity, put/call options, etc.). This is not an AGM presentation, full annual or interim report, nor a transcript or voting notice. It is an announcement of a financing transaction (convertible bond issuance), which falls under Capital/Financing Update.
2026-04-17 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 공식 주요사항보고서 filed with the Financial Services Commission and Korea Exchange, detailing a 유상증자결정 (third‐party allocation capital increase) including share types, issuance terms, conversion mechanics, use of proceeds, allocation to specific investors, subscription rights and other issuance conditions. It is not a high‐level summary or presentation, nor an earnings or management report, but a formal announcement of a new share issue/capital change. This matches the definition for Share Issue/Capital Change (Code: SHA).
2026-04-17 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.